Radiosensitization of murine Ehrlich ascites tumor by a combination of 2-deoxy-D-glucose and 6-aminonicotinamide.

Enhanced radiosensitizing effects of a combination of 2-deoxy-D-glucose (2-DG), a glycolytic inhibitor and 6-aminonicotinamide (6-AN) an analogue of nicotinamide, which inhibits hexose monophosphate shunt (HMP) have been demonstrated in vitro. The purpose of the present studies is to investigate in vivo effects of this combination in Ehrlich ascites tumor (EAT) bearing mice. EAT tumor was grown in Swiss albino strain A mice. Treatment induced growth delay and tumor free animal survival were evaluated as parameters of radiation response. Focal irradiation of the tumor with a single fraction of 10 Gy induced a moderate delay in tumor growth but did not lead to complete regression of the tumor. Intravenous administration of either 6-AN or 2-DG immediately before irradiation enhanced radiation-induced growth delay with a cure rate of 45%. However, administration of a combination of 2-DG (2 g/kg b.wt.) and 6-AN (2 mg/kg b.wt.) immediately before irradiation led to complete regression of tumor in 80% animals resulting in survival of more than 300 days. A similar response (approximately 80%) was observed when 2-DG dose was reduced to 1 g/kg in combination with 6-AN. It is concluded that 6-AN enhances the radiosensitizing effects of 2-DG and the combination may have potential application in improving radiotherapy of tumors.
AuthorsR Varshney, S Gupta, B S Dwarakanath
JournalTechnology in cancer research & treatment (Technol Cancer Res Treat) Vol. 3 Issue 6 Pg. 659-63 (Dec 2004) ISSN: 1533-0346 [Print] United States
PMID15560724 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Radiation-Sensitizing Agents
  • 6-Aminonicotinamide
  • Deoxyglucose
  • 6-Aminonicotinamide (administration & dosage, pharmacology)
  • Animals
  • Carcinoma, Ehrlich Tumor (drug therapy, pathology, radiotherapy)
  • Deoxyglucose (administration & dosage, pharmacology)
  • Dose-Response Relationship, Radiation
  • Mice
  • Neoplasm Transplantation
  • Radiation-Sensitizing Agents (administration & dosage, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: